We call the 25-year-old cancer survivor a medical miracle, yet we're mostly silent about the fact that her endocrine system just aged thirty years overnight.

Modern oncofertility is fixated on cellular salvage. We’re essentially raiding the bank for the gold—the oocytes—while letting the vault burn. By saving the "seeds" but torching the "soil," we shouldn’t be shocked when systemic issues like osteoporosis, cardiovascular decay, and cognitive decline show up a decade early.

The real damage isn't just the lost eggs; it’s the fibrotic collapse of the ovarian cortical stroma. Chemotherapy and radiation don't just clear out germ cells. They trigger acute, permanent senescence in the follicular microenvironment, turning it into a pro-inflammatory signaling hub. This localized senescence-associated secretory phenotype (SASP) then radiates aging signals throughout the body long after the cancer is gone.

I’m looking for partners to help launch the Stroma-Shield Initiative. Cryopreservation isn't enough anymore; we need proactive niche protection. Our goal is to validate a protocol for the co-administration of localized senomorphic cocktails during chemotherapy. We aren't trying to shield the tumor; we’re trying to stop the ovarian stroma from spiraling into a death spiral of cross-linking and fibrosis. If we can maintain the physical elasticity and signaling integrity of that environment, we don't just preserve fertility—we maintain the endogenous hormonal rhythm that keeps the rest of the female body healthy.

I want to hear from reproductive endocrinologists, stromal biologists, and pharmacologists who don't think "survival" should mean a state of accelerated decay. We have the tools to prevent this iatrogenic aging burst. We just need to stop treating the ovaries as disposable assets once their reproductive utility is tucked away in a freezer.

Who’s ready to end this scorched-earth policy?